Apremilast and Adalimumab in Psoriatic Arthritis Patients

Starting soon · Not applicable

Conditions studied: Psoriatic Arthritis, Ultrasound Assessment, TNF

In brief

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

Key facts

Study ID

NCT07398651

Run by

Tanta University

People needed

60

Starts

2026-12-30

Expected to finish

2026-12-30

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• This study will include 60 adult Psoriatic arthritis patients >18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.
• Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains

You may not qualify if…

• Patients who received previous biologic agents or Janus kinase inhibitors.
• Patients with axial and ocular involvement.
• Current or recent serious infection including tuberculosis or hepatitis B/C .
• Current or past history of malignancy (within five year).
• Pregnant or breastfeeding women or women planning pregnancy during the study period .
• Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR <30 mL/min/1.73m²) .

Where it is running

• Tanta University — Tanta, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.